Company Profile
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Latest News
Earnings Calendar and Analysis for This Week (July 27-31)
Omnicell to Report Q2 Earnings: OmniSphere in Focus
2 Cash-Heavy Stocks to Target This Week and 1 We Turn Down
1 Healthcare Stock to Target This Week and 2 We Brush Off
Unpacking Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) In The Context Of Other Healthcare Technology Stocks
| Sector | Healthcare |
| Industry | Health Information Services |
| Website | https://www.omnicell.com |
| Audit Risk | 2 |
| Board Risk | 5 |
| Overall Risk | 5 |
| Market Cap | 1.86B |
| Trailing P/E | 93.18 |
| Forward P/E | 18.68 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | 0.44 |
| Forward EPS | 2.2 |
| Book Value | 27.63 |
| Price-to-Book | 1.48 |
| Enterprise-to-Revenue | 1.49 |
| Enterprise-to-EBITDA | 24.83 |
| Short Ratio | 4.73 |
| Earnings Date | 07/30/2026 |
| Earnings Call Date | 07/30/2026 |
| Earnings Average | 0.47 |
| Earnings Low | 0.44 |
| Earnings High | 0.48 |
| Revenue Average | 310.22M |
| Revenue Low | 309.00M |
| Revenue High | 311.26M |